Q&A: The $69 billion acquisition may hinge on the Trump administration’s approach to antitrust enforcement.
A drugstore chain that used to hawk cigarettes behind the front counter now wants to offer nutrition advice and work with your doctor to keep you healthy.
CVS Health says it wants to use its roughly $69 billion acquisition of the insurer Aetna to dive deeper into managing customer health, with its nearly 10,000 stores becoming “front doors” for care. The companies plan to expand the health services offered through CVS locations and get more involved in helping patients stay on their medicines or manage their chronic conditions.
The deal announced Sunday will pair the second-largest U.S. drugstore chain with the third-largest health insurer. Here’s how it will likely play out.
Q: How will stores change?
Most Read Business Stories
- Foreign tech workers face higher hurdles in H-1B visa applications
- Some Pacific Northwest CEOs earn 200 or 400 times what the average employee is paid
- As the Farnborough Air Show ends, Boeing emerges clearly ahead
- Boeing can't wrest away big Airbus customer's A330neo order
- Amazon announces plans for Spokane warehouse, first Eastern Washington outpost
A: The deal pushes CVS further down a path it started years ago when it began adding clinics to its stores and later quit selling tobacco. Over time, CVS plans to bulk up the health-care services it offers through its stores and the space it devotes to them.
The company already has started testing vision and hearing-aid centers at 15 and 32 locations, respectively. It also does blood draws and monitors chronic conditions like high blood pressure at certain stores.
The company might add to the 1,100 clinics it operates, expand into selling more medical equipment or offer nutritionists to counsel customers.
CVS leaders think its vast footprint — nearly 70 percent of the U.S. population lives within 3 miles of a CVS pharmacy — gives it an opportunity to build a deeper relationship with customers.
Q: Are they trying to replace my family doctor?
A: CVS wants to complement doctor care, CEO Larry Merlo said Monday during a conference call to discuss the deal.
For example, Merlo said people with diabetes typically see their doctor several times a year but may have trouble sticking with a treatment plan. The company said it can help patients stay on a plan, using its network of pharmacists, clinics and other future services.
“We’re in the community, we’re seeing those patients. We’re becoming part of their daily lives and routines,” he said.
Q: Will this make my prescription drugs cheaper?
A: Not in the near term, according to Edward Jones analyst John Boylan.
The deal doesn’t change how drugs are priced. It just puts key players in that negotiation — drugstores and pharmacy benefits managers — under the same roof as an insurer, Boylan said.
CVS processes more than a billion prescriptions annually as one of the nation’s largest pharmacy benefit managers, running prescription-drug coverage for large clients like Aetna.
Over time, a bulked-up CVS may gain some negotiating power over prescription prices, but it’s hard to say whether that will translate to lower prices for consumers.
The deal could make other care elements cheaper, especially for Aetna customers who might get incentives like no co-payments to encourage use of CVS clinics for basic, nonemergency care.
Q: What’s the business case for this deal?
A: Buying Aetna gives CVS a way to better compete with other huge national health- care companies like UnitedHealth Group. The nation’s largest insurer also runs a big pharmacy benefit management business and operates clinics and doctor offices.
Aetna will operate as a separate brand inside CVS. The deal also will help CVS keep competitors from poaching its 22 million customers.
Retailers like CVS face growing online competition, especially for the consumer products they sell outside store pharmacies. By adding more services, the drugstores will be selling something customers cannot buy online.
CVS also hopes to get customers to use its stores and services more. Drugstores have learned that customers aren’t particularly loyal to one chain and will fill their prescriptions where their coverage tells them or where they can get the best deal.
Q: When will this deal close?
A: The companies expect that to happen in the second half of next year. However, it still has to pass federal antitrust scrutiny.
Deal may hinge on antitrust approach
CVS Health’s plan to take over Aetna will test the Trump administration’s approach to far-reaching corporate takeovers, just weeks after the U.S. government sued to block a major telecommunications merger.
In the past, deals combining companies up and down a chain of business — such as a supplier and a distributor — have been viewed as posing less anticompetitive risk than combinations of direct rivals. Last month, however, the Justice Department sued to block just such a “vertical” merger between AT&T and Time Warner, saying it would harm consumers and limit their media content options.
How much scrutiny the deal gets from the government may depend on which federal agency reviews the takeover: the Justice Departmen or the Federal Trade Commission.
The FTC has typically handled mergers of retail businesses like CVS. While it allowed Walgreens to buy more than 1,900 Rite Aid stores earlier this year, the deal had to be significantly scaled down to gain the regulator’s approval. The Justice Department, meanwhile, successfully sued to block insurance mergers between Anthem and Cigna, and Aetna and Humana.
In the past, vertical deals have typically won approval after companies agree to restrictions on how they operate. That may be changing. The Justice Department’s new antitrust chief, Makan Delrahim, has criticized past settlements that allowed vertical deals with behavioral restrictions. In a speech last month, Delrahim said such conditions don’t work and force antitrust enforcers to become regulators.
That doesn’t mean there’s heightened hostility toward vertical deals at the Justice Department, but CVS might prefer the Aetna deal to go to the FTC given Delrahim’s criticism of behavioral fixes, said David Kully, an antitrust lawyer at Holland & Knight in Washington and a former Justice Department attorney.
Bloomberg News reporters